Quantcast

Latest H5N1 clinical trials Stories

a09cd1217ea4e362ec838d21fbc68bb71
2009-09-22 11:50:42

Early results from a trial of H1N1 influenza vaccine in children shows the vaccine appears to be as effective as in the trial in adults, U.S. researchers said. Officials at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, said the preliminary analysis of blood samples from a small group of trial participants showed a single 15-microgram dose of a non-adjuvanted H1N1 vaccine generates an immune response expected to be protective against in...

2009-09-21 11:13:00

LYON, France and SWIFTWATER, Pa., Sept. 21 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that the company has received an additional order from the U.S. Department of Health and Human Services (HHS) to produce vaccine to help protect against the Influenza A (H1N1) 2009 virus. The new order is for the production of bulk antigen equivalent to 27.3 million doses based on 15 mcg of antigen per dose....

2009-09-17 16:56:47

The United States is prepared to make 10 percent of its H1N1 vaccine supply available to other countries, an announcement by the White House said Thursday. In recognition that diseases know no borders and that the health of the American people is inseparable from the health of people around the world, the United States is taking this action in concert with Australia, Brazil, France, Italy, New Zealand, Norway, Switzerland, and the United Kingdom, the White House statement said. The United...

2009-09-15 23:01:00

ROCKVILLE, Md., Sept. 16 /PRNewswire-USNewswire/ -- Sanaria Inc. has received additional support from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The award for two years is $1.99 million. Subject to satisfactory progress by Sanaria, continued funding for a third year will bring the total to nearly $3 million. This new funding will facilitate efforts to...

2009-09-15 14:34:00

Approval Provides Important Tool to Fight Pandemic WASHINGTON, Sept. 15 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration announced today that it has approved four vaccines against the 2009 H1N1 influenza virus. The vaccines will be distributed nationally after the initial lots become available, which is expected within the next four weeks. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) "Today's approval is good news for our nation's response to the 2009...

2009-09-15 14:22:00

LYON, France and SWIFTWATER, Pa., Sept. 15 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental biologics license application (sBLA) for licensure of its Influenza A (H1N1) 2009 Monovalent Vaccine. The U.S. licensed Influenza A (H1N1) 2009 Monovalent Vaccine is an inactivated influenza virus vaccine indicated for active...

2009-09-14 10:16:18

U.S. officials said they are encouraged by the progress of various clinical trials of H1N1 influenza vaccines. The early data from these trials indicate the H1N1 influenza vaccines are well tolerated and induce a strong immune response in most healthy adults when administered in a single unadjuvanted 15-microgram dose, said a statement by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. NIAID is also conducting clinical trials of H1N1...

2009-09-09 12:43:05

Researchers in New York say they have identified two protein fragments that could be developed into a new anthrax vaccine. Scientists from Yeshiva University's Albert Einstein College of Medicine said their research suggests the protein fragments could lead to a vaccine with fewer side effects than the current vaccine. Our research was motivated by the fact that the current anthrax vaccine has significant limitations and there is great need for a better one, said postdoctoral fellow Nareen...

2009-09-08 09:00:00

SAN FRANCISCO, Sept. 8 /PRNewswire/ -- Vaxart, Inc., a San Francisco biotechnology company developing oral-delivery vaccines, has been awarded a $2.8 million phase II Small Business Innovation Research grant from the National Institute of Allergy and Infectious Disease (National Institutes of Health) to support development of its first product, an orally-delivered vaccine for H5N1 Avian influenza. "We thank the NIH for funding the further safety and efficacy tests, which, along with our...

2009-09-08 05:00:00

BOZEMAN, Mont., Sept 8 /PRNewswire/ -- LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will assess safety and immunogenicity associated with LigoCyte's investigational, nasally-delivered, dry powder vaccine in healthy adults. The study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related